Alpha 1 Antitrypsin (AAT) deficiency is a hereditary condition that can severely affect the function of a patient’s lung. The condition is marked by a low level or absence of Alpha 1 Antitrypsin, a natural protein that inhibits neutrophil elastase to prevent the destruction of lung tissue. Severe deficiency of AAT is associated with a strong tendency for the development of emphysema, a form of COPD, and can significantly impact everyday life and life expectancy of patients. Our plasma derived protein product has been proven to raise and maintain AAT serum levels in patients with AAT deficiency and clinical evidence of emphysema.
Some of the most common respiratory diseases are chronic obstructive pulmonary disease (COPD) and asthma. We are currently developing a nebulised Immunoglobulin (Ig) formulation which may potentially reduce the frequency of respiratory infections or symptoms of chronic lung disease in patients with COPD. Generally immunoglobulins (Ig) are administered intravenously or subcutaneously. In our effort to innovate for patients, CSL is studying a new route of administration via aerosolised delivery to the respiratory tract.
We are also developing a novel monoclonal antibody, CSL311, which neutralises the ß-common receptor associated with the development of chronic inflammatory diseases such as asthma. CSL311 is currently being investigated in preclinical studies to support progression into clinical trials later in 2019 to potentially improve the life of patients with severe uncontrolled asthma in the future.